Subscribe To
RNAZ / TransCode Therapeutics to Present at 2020 BIO CEO & INVESTOR CONFERENCE
RNAZ News
By InvestorPlace
October 27, 2023
Why Is TransCode Therapeutics (RNAZ) Stock Down 25% Today?
TransCode Therapeutics (NASDAQ: RNAZ ) stock is taking a beating on Friday after the oncology company announced plans for a public share offering. Tr more_horizontal
By InvestorPlace
September 26, 2023
Why Is TransCode Therapeutics (RNAZ) Stock Down 69% Today?
TransCode Therapeutics (NASDAQ: RNAZ ) stock is falling hard on Tuesday after the medical company announced a public share offering. According to a p more_horizontal
By Proactive Investors
September 26, 2023
Transcode Therapeutic stock whipsaws lower after cut price placing
TransCode Therapeutics (NASDAQ:RNAZ) stock has seen a wild 24 hours of trading as the Boston headquartered nano-cap drug discovery firm rocketed Monda more_horizontal
By Proactive Investors
September 25, 2023
TransCode Therapeutics stock skyrockets on positive brain cancer trial results
TransCode Therapeutics (NASDAQ:RNAZ) shares took off after it announced positive results from a study of its lead drug candidate TTX-MC138 in mice mod more_horizontal
By Zacks Investment Research
July 10, 2023
TransCode Therapeutics Inc. (RNAZ) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
TransCode Therapeutics Inc. (RNAZ) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In a more_horizontal
By Pulse2
February 20, 2023
RNAZ Stock: 4.96% This Week Explanation
The stock price of TransCode Therapeutics, Inc. (Nasdaq: RNAZ) increased by 4.96% this past week. This is why. more_horizontal
By InvestorPlace
February 1, 2023
Why Is TransCode Therapeutics (RNAZ) Stock Up 45% Today?
TransCode Therapeutics (NASDAQ: RNAZ ) stock is rocketing higher on Wednesday following positive study results. The big news here has to do with TTX-R more_horizontal
By InvestorPlace
December 7, 2022
Why Is TransCode Therapeutics (RNAZ) Stock Up 148% Today?
TransCode Therapeutics (NASDAQ: RNAZ ) stock is rallying higher on Wednesday after the company withdrew plans for a secondary offering. According to t more_horizontal